Partners, L.P.Broadwood Cap... Net Worth

The estimated Net Worth of Partners, L.P.Broadwood Cap... is at least $219 Milhão dollars as of 9 May 2024. Partners Cap owns over 1 units of Lineage Cell Therapeutics Inc stock worth over $9,316,847 and over the last 17 years Partners sold LCTX stock worth over $209,947,999.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Partners Cap LCTX stock SEC Form 4 insiders trading

Partners has made over 96 trades of the Lineage Cell Therapeutics Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Partners bought 1 units of LCTX stock worth $43 on 9 May 2024.

The largest trade Partners's ever made was buying 26,827,638 units of Lineage Cell Therapeutics Inc stock on 3 April 2023 worth over $8,048,291. On average, Partners trades about 677,408 units every 55 days since 2007. As of 9 May 2024 Partners still owns at least 10,768,431 units of Lineage Cell Therapeutics Inc stock.

You can see the complete history of Partners Cap stock trades at the bottom of the page.

Insiders trading at Lineage Cell Therapeutics Inc

Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley, eBrian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.

What does Lineage Cell Therapeutics Inc do?

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Complete history of Partners Cap stock trades at Staar Surgical Co, Oncocyte, eLineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc executives and stock owners

Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include:

• Brandi Roberts,
  Chief Financial Officer
• Brian M. Culley M.A., M.B.A.,
  CEO, Pres & Director
• Brian Culley,
  Chief Executive Officer, Director
• Chase Leavitt,
  General Counsel and Corporate Secretary
• Brandi L. Roberts,
  Consultant
• Angus Russell,
  Independent Director
• Michael Mulroy,
  Independent Director
• Stephen Farrell,
  Independent Director
• Neal Bradsher,
  Independent Director
• Don Bailey,
  Independent Director
• Deborah Andrews,
  Independent Director
• Gary Hogge,
  Senior Vice President of Clinical & Medical Affairs
• Alfred Kingsley,
  Chairman of the Board
• Alexandra Hernandez,
  Sr. Director of Fin. & Controller
• Dr. Rami Skaliter,
  Chief Exec. Officer of Cell Cure Neurosciences Ltd.
• William Annett,
  Pres & CEO of OncoCyte Corp.
• Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.,
  Sr. VP of Clinical & Medical Affairs
• Dr. François Binette M.Sc., Ph.D.,
  Sr. VP & Global Head of R&D
• George A. Samuel III, J.D.,
  Gen. Counsel & Company Sec.
• Ioana C. Hone,
  Director of Investor Relations
• Kevin L. Cook,
  Chief Financial Officer
• George A. Iii Samuel,
  General Counsel/Secretary
• Anula Jayasuriya,
  
• Dipti Amin,
  
• Neal C Bradsher,
  Director
• Alexandra Hernandez,
  Sr Director Finance/Controller
• Kevin Leon Cook,
  Chief Financial Officer
• Jill Ann Howe,
  Chief Financial Officer